Habib M, Tokutake Y, Yonekura S
Anim Sci J. 2025; 96(1):e70038.
PMID: 39930899
PMC: 11811678.
DOI: 10.1111/asj.70038.
Chen W, Zhang J, Chen L, Byrne C, Targher G, Luo L
Clin Mol Hepatol. 2024; 31(1):56-73.
PMID: 39428978
PMC: 11791555.
DOI: 10.3350/cmh.2024.0782.
Lenci I, Milana M, Signorello A, Grassi G, Baiocchi L
World J Gastroenterol. 2023; 29(2):357-366.
PMID: 36687129
PMC: 9846939.
DOI: 10.3748/wjg.v29.i2.357.
Han Y, Jeong H, Kim E, Boud F, Lim S, Lee S
Yonsei Med J. 2021; 62(6):555-562.
PMID: 34027643
PMC: 8149933.
DOI: 10.3349/ymj.2021.62.6.555.
Simental-Mendia L, Simental-Mendia M, Sanchez-Garcia A, Banach M, Serban M, Cicero A
Lipids Health Dis. 2019; 18(1):88.
PMID: 30954082
PMC: 6451779.
DOI: 10.1186/s12944-019-1041-4.
Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.
Kim D, Chung H, Ji S, Lee S, Yu K, Jang I
Metabolomics. 2019; 15(3):30.
PMID: 30830474
DOI: 10.1007/s11306-019-1494-5.
Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment.
Zaborska K, Cummings B
Curr Diab Rep. 2018; 18(11):109.
PMID: 30232649
DOI: 10.1007/s11892-018-1092-3.
NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.
Tang Y, Blomenkamp K, Fickert P, Trauner M, Teckman J
PLoS One. 2018; 13(8):e0200897.
PMID: 30067827
PMC: 6070232.
DOI: 10.1371/journal.pone.0200897.
Ursodeoxycholic Acid Inhibits Inflammatory Responses and Promotes Functional Recovery After Spinal Cord Injury in Rats.
Ko W, Kim S, Jo M, Choi H, Lee D, Kwon I
Mol Neurobiol. 2018; 56(1):267-277.
PMID: 29691718
DOI: 10.1007/s12035-018-0994-z.
Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages.
Ko W, Lee S, Kim S, Jo M, Kumar H, Han I
PLoS One. 2017; 12(6):e0180673.
PMID: 28665991
PMC: 5493427.
DOI: 10.1371/journal.pone.0180673.
A biosynthetic pathway for a prominent class of microbiota-derived bile acids.
Devlin A, Fischbach M
Nat Chem Biol. 2015; 11(9):685-90.
PMID: 26192599
PMC: 4543561.
DOI: 10.1038/nchembio.1864.
Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review.
Wang D, Carey M
World J Gastroenterol. 2014; 20(29):9952-75.
PMID: 25110425
PMC: 4123376.
DOI: 10.3748/wjg.v20.i29.9952.
Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.
Shih D, Shaposhnik Z, Meng Y, Rosales M, Wang X, Wu J
FASEB J. 2013; 27(9):3805-17.
PMID: 23752203
PMC: 3752541.
DOI: 10.1096/fj.12-223008.
Contribution of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon.
Lee J, Arai H, Nakamura Y, Fukiya S, Wada M, Yokota A
J Lipid Res. 2013; 54(11):3062-9.
PMID: 23729502
PMC: 3793610.
DOI: 10.1194/jlr.M039834.
Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb M
Int J Mol Sci. 2012; 13(7):8882-8914.
PMID: 22942741
PMC: 3430272.
DOI: 10.3390/ijms13078882.
No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
Xiang X, Vakkilainen J, Backman J, Neuvonen P, Niemi M
Eur J Clin Pharmacol. 2011; 67(11):1159-67.
PMID: 21655991
DOI: 10.1007/s00228-011-1070-z.
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E, Marschall H, Kowdley K, Befeler A, Keach J, Lindor K
Hepatology. 2010; 52(1):197-203.
PMID: 20564380
PMC: 2928060.
DOI: 10.1002/hep.23631.
Bile acids in treatment of ocular disease.
Boatright J, Nickerson J, Moring A, Pardue M
J Ocul Biol Dis Infor. 2010; 2(3):149-159.
PMID: 20046852
PMC: 2798994.
DOI: 10.1007/s12177-009-9030-x.
Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: review of a historical cohort.
Kotb M
Dig Dis Sci. 2008; 54(10):2231-41.
PMID: 19082720
DOI: 10.1007/s10620-008-0600-8.
Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex.
Yue P, Zhang W, Yuan H, Yang M, Zhu W, Cai P
AAPS PharmSciTech. 2008; 9(1):322-9.
PMID: 18446498
PMC: 2976878.
DOI: 10.1208/s12249-008-9040-1.
